(Q34810745)

4 August 2017

1 reference

title

Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer (English)

1 reference

4 August 2017

1 reference

1 reference

Helmut Oettle

1

1 reference

4 August 2017

Hanno Riess

series ordinal

2

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

4 August 2017

1 reference

4 August 2017

95

1 reference

4 August 2017

4 Suppl

1 reference

4 August 2017

912-922

1 reference

Chemotherapy for pancreatic carcinoma

4 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

Phase II study of gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

7 January 2021

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

7 January 2021

A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

7 January 2021

Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

7 January 2021

A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

7 January 2021

Proposing phase I studies: patients', relatives', nurses' and specialists' perceptions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

7 January 2021

A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

7 January 2021

Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10758

7 January 2021

Identifiers

DOI

10.1002/CNCR.10758

1 reference

release_hnmqcikbcff2bosap62rhslnne

4 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hnmqcikbcff2bosap62rhslnne

24 November 2022

mapped directly with Wikidata item

1 reference